Lars Engstrom

Lars Engstrom has over 20 years of work experience in the field of pharmaceutical research and molecular biology. Lars started their career at the University of Michigan - Comprehensive Cancer Center, where they worked as a Research Associate II. During their time there, Lars managed a molecular biology laboratory and was responsible for individual research projects exploring a tumor suppressor gene.

In 2002, Lars transitioned into industry and joined Pfizer as a Senior Associate Scientist in the Drug Safety R&D department. Their role included developing novel biomarkers and imaging methods, specifically focusing on hepatic endothelial cell proliferation. Lars played a significant role in providing data for the FDA approval of the drug Lyrica.

In 2007, Lars advanced within Pfizer to become a Senior Scientist in the Oncology Research unit. During this role, they successfully led multiple early-stage oncology projects, progressing them from target validation to development. Lars was involved in the development of in vitro assays and engineered cell lines to identify effective treatments against crizotinib resistant mutations.

Since 2013, Lars has been working at Mirati Therapeutics. Lars initially held the position of Senior Scientist, where they continued to contribute to the company's oncology research. From there, they progressed to become a Principal Scientist and is currently serving as a Senior Principal Scientist.

Throughout their career, Lars has demonstrated expertise in molecular biology, assay development, imaging methods, and project management. Lars has a strong track record of contributing to the advancement of therapeutic research in the oncology field.

Lars Engstrom received their Bachelor of Science (BS) degree from the University of Michigan, where they studied from 1997 to 1999. Prior to that, they attended Albion College from 1995 to 1997, majoring in Biology and Economics.